Köster Ingrid, Schubert Ingrid, Huppertz Eduard
Dtsch Med Wochenschr. 2012 May;137(19):1013-6. doi: 10.1055/s-0032-1304891. Epub 2012 Apr 27.
Cost of illness studies create transparency on the economic dimension of diseases. By now, the CoDiM study, based on administrative data of AOK Hesse und KV Hesse, identifies costs of people with diabetes and diabetes related excess costs in Germany for a period of 10 years. To date, additionally adjusted results are available by accounting for effects caused by inflation and ageing of the population. From 2000 to 2009 the number of treated patients with diabetes increased by 49 %, adjusted for age by 31 %. Mean cost of patients with diabetes and diabetes related excess costs per capita turned out to be relatively stable over the time period observed. The relation of cost per patient with diabetes to cost of patients without diabetes didn't change. Due to the increase of the number of treated patients with diabetes in the past 10 years, the total direct cost, dependant on the approach of calculation (adjusting or not for inflation and ageing effects), rose by 28 % to 70 %, the therein included diabetes excess cost by 24 % to 61 %.
疾病成本研究揭示了疾病经济层面的透明度。目前，基于黑森州法定医疗保险基金（AOK Hesse）和黑森州矿工联合会（KV Hesse）行政数据的CoDiM研究，确定了德国糖尿病患者的成本以及与糖尿病相关的额外成本，为期10年。到目前为止，通过考虑通货膨胀和人口老龄化造成的影响，还可获得经过调整的结果。从2000年到2009年，接受治疗的糖尿病患者数量增加了49%，经年龄调整后增加了31%。在观察期内，糖尿病患者及与糖尿病相关的人均额外成本相对稳定。糖尿病患者人均成本与非糖尿病患者成本的关系没有变化。由于过去10年中接受治疗的糖尿病患者数量增加，根据计算方法（是否调整通货膨胀和老龄化影响），直接总成本上升了28%至70%，其中包括的糖尿病额外成本上升了24%至61%。
